Morgan Stanley
VIRX

Morgan Stanley’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Morgan Stanley’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,135
Closed -$5.81K – 8313
2024
Q4 		$5.81K Buy
36,135
+5,466
+18% +$1.08K ﹤0.01% 6968
2024
Q3 		$7.1K Sell
30,669
-103,875
-77% -$38.1K ﹤0.01% 6813
2024
Q2 		$73.2K Buy
134,544
+16,528
+14% +$13K ﹤0.01% 6064
2024
Q1 		$120K Sell
118,016
-56,666
-32% -$41.4K ﹤0.01% 5917
2023
Q4 		$99.6K Buy
174,682
+114,456
+190% +$70.2K ﹤0.01% 6164
2023
Q3 		$62.6K Buy
60,226
+1,376
+2% +$1.87K ﹤0.01% 6071
2023
Q2 		$83K Buy
58,850
+2,964
+5% +$4.24K ﹤0.01% 6021
2023
Q1 		$88.9K Sell
55,886
-6,095
-10% -$11.1K ﹤0.01% 6056
2022
Q4 		$90.5K Sell
61,981
-4,211
-6% -$12.3K ﹤0.01% 6021
2022
Q3 		$282K Sell
66,192
-22,104
-25% -$93.6K ﹤0.01% 5561
2022
Q2 		$343K Buy
88,296
+20,594
+30% +$58.7K ﹤0.01% 5614
2022
Q1 		$322K Sell
67,702
-508,375
-88% -$1.53M ﹤0.01% 5651
2021
Q4 		$2.1M Buy
576,077
+544,576
+1,729% +$2.91M ﹤0.01% 4546
2021
Q3 		$253K Sell
31,501
-4,445
-12% -$43.8K ﹤0.01% 5877
2021
Q2 		$407K Sell
35,946
-4,648
-11% -$46.6K ﹤0.01% 5653
2021
Q1 		$375K Buy
40,594
+39,560
+3,826% +$412K ﹤0.01% 5313
2020
Q4 		$7K Buy
1,034
+406
+65% +$2.12K ﹤0.01% 6722
2020
Q3 		$2K Buy
628
+20
+3% +$175 ﹤0.01% 6601
2020
Q2 		$5K Buy
608
+450
+285% +$6.78K ﹤0.01% 6308
2020
Q1 		$2K Sell
158
-264
-63% -$5.73K ﹤0.01% 6411
2019
Q4 		$5K Sell
422
-535
-56% -$8.96K ﹤0.01% 6402
2019
Q3 		$24K Buy
957
+258
+37% +$7.45K ﹤0.01% 5958
2019
Q2 		$18K Sell
699
-272
-28% -$10.5K ﹤0.01% 5974
2019
Q1 		$41K Sell
971
-134
-12% -$3.04K ﹤0.01% 5756
2018
Q4 		$15K Buy
1,105
+802
+265% +$32.7K ﹤0.01% 6079
2018
Q3 		$21K Sell
303
-371
-55% -$28.2K ﹤0.01% 6126
2018
Q2 		$50K Sell
674
-92
-12% -$8.19K ﹤0.01% 5919
2018
Q1 		$73K Buy
766
+127
+20% +$21.8K ﹤0.01% 5792
2017
Q4 		$82K Sell
639
-127
-17% -$11.9K ﹤0.01% 5697
2017
Q3 		$52K Sell
766
-101
-12% -$8.25K ﹤0.01% 5773
2017
Q2 		$82K Sell
867
-107
-11% -$12.3K ﹤0.01% 5710
2017
Q1 		$139K Buy
974
+862
+770% +$123K ﹤0.01% 5482
2016
Q4 		$14K Sell
112
-30
-21% -$4.18K ﹤0.01% 6086
2016
Q3 		$22K Sell
142
-66
-32% -$9.31K ﹤0.01% 5890
2016
Q2 		$24K Sell
208
-139
-40% -$15.4K ﹤0.01% 5789
2016
Q1 		$40K Sell
347
-14
-4% -$2.12K ﹤0.01% 5695
2015
Q4 		$68K Sell
361
-780
-68% -$146K ﹤0.01% 5600
2015
Q3 		$193K Sell
1,141
-1,071
-48% -$386K ﹤0.01% 5107
2015
Q2 		$1.4M Sell
2,212
-731
-25% -$388K ﹤0.01% 3943
2015
Q1 		$1.51M Sell
2,943
-1,860
-39% -$938K ﹤0.01% 3811
2014
Q4 		$2.57M Buy
4,803
+4,661
+3,282% +$2.1M ﹤0.01% 3335
2014
Q3 		$213K Sell
142
-53
-27% -$76.7K ﹤0.01% 5111
2014
Q2 		$266K Buy
195
+160
+457% +$186K ﹤0.01% 5006
2014
Q1 		$48K Sell
35
-289
-89% -$336K ﹤0.01% 5730
2013
Q4 		$322K Buy
324
+259
+398% +$268K ﹤0.01% 4778
2013
Q3 		$68K Sell
65
-90
-58% -$96.2K ﹤0.01% 5158
2013
Q2 		$169K Buy
+155
New +$173K ﹤0.01% 4913

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Morgan Stanley's VIRX Position: Q1 2025 in Review

Morgan Stanley sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 36,135 shares — an estimated $5.81K sold.

Morgan Stanley first reported a position in VIRX in Q2 2013 and held it in 47 quarters. The position peaked at $2.57M in Q4 2014. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Morgan Stanley reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 36,135 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $5.81K.
  • Morgan Stanley first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 47 quarters.
  • Morgan Stanley's Viracta Therapeutics, Inc. Common Stock position peaked at $2.57M in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.